Rusconi S - Search Results

1

A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.

Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, Di Giambenedetto S. Ciccullo A, et al. Among authors: rusconi s. Antivir Ther. 2019;24(1):63-67. doi: 10.3851/IMP3270. Antivir Ther. 2019. PMID: 30277466

2

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. d'Arminio Monforte A, et al. Among authors: rusconi s. AIDS. 1998 Sep 10;12(13):1631-7. doi: 10.1097/00002030-199813000-00010. AIDS. 1998. PMID: 9764782 Clinical Trial.

3

Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.

Bongiovanni M, Bini T, Tordato F, Cicconi P, Melzi S, Repetto D, Sollima S, Rusconi S, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: rusconi s. J Antimicrob Chemother. 2003 Jan;51(1):171-4. doi: 10.1093/jac/dkg045. J Antimicrob Chemother. 2003. PMID: 12493805 Free article.

4

Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A. Chiesa E, et al. Among authors: rusconi s. Antivir Ther. 2003 Feb;8(1):27-35. Antivir Ther. 2003. PMID: 12713061

5

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

Bongiovanni M, Bini T, Adorni F, Meraviglia P, Capetti A, Tordato F, Cicconi P, Chiesa E, Cordier L, Cargnel A, Landonio S, Rusconi S, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: rusconi s. Antivir Ther. 2003 Jun;8(3):209-14. Antivir Ther. 2003. PMID: 12924537 Clinical Trial.

6

Efficacy and tolerability of multiple drug therapy in HIV-infected children.

Viganò A, Schneider L, Giacomet V, Bianchi R, Cicero ML, Soster F, Bulgheroni E, Rusconi S. Viganò A, et al. Among authors: rusconi s. J Infect. 2005 Jun;50(5):404-11. doi: 10.1016/j.jinf.2004.08.001. J Infect. 2005. PMID: 15907548 Free article.

7

Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients.

Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, Galli M, Riva A; rHoPeS Group. Mologni D, et al. Among authors: rusconi s. AIDS. 2006 Feb 28;20(4):567-74. doi: 10.1097/01.aids.0000210611.60459.0e. AIDS. 2006. PMID: 16470121

8

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.

Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. Among authors: rusconi s. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.

9

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785

10

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.

Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A; ARCA database initiative. Gianotti N, et al. J Med Virol. 2011 Mar;83(3):391-8. doi: 10.1002/jmv.21989. J Med Virol. 2011. PMID: 21264858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

430 results

Search Page

Filters